Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related claims about serious infections and infection screening/monitoring are broadly consistent with the boxed warning language; however, multiple claims about ulcerative colitis use, biologic timing/positioning, and treatment “generally used” criteria are not supported by the prescribing information excerpts provided.
Category Scores
Accurate Statements
Infliximab carries class-related risks including serious infections.
BOXED WARNING — SERIOUS INFECTIONS: “Patients treated with REMICADE are at increased risk for developing serious infections that may lead to hospitalization or death.”
Clinicians typically screen for infection risks (such as tuberculosis) before starting infliximab.
BOXED WARNING — SERIOUS INFECTIONS: “Patients should be tested for latent tuberculosis before REMICADE use and during therapy. Treatment for latent infection should be initiated prior to REMICADE use.”
Clinicians monitor patients during infliximab treatment.
BOXED WARNING — SERIOUS INFECTIONS: “Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment…”
Unsupported Statements
Remicade (infliximab) is used to treat ulcerative colitis (UC).
The provided FDA label excerpts include no Indications and Usage text supporting UC use.
Remicade is used for moderate to severe UC.
No Indications and Usage excerpt is provided to support severity wording for UC.
Remicade is used when UC needs biologic therapy rather than only standard treatments like aminosalicylates or steroids.
No label excerpt is provided describing step therapy or comparisons to aminosalicylates/steroids.
In UC, infliximab (Remicade) is generally used for people with moderate to severe disease who have not responded adequately to other treatments.
No label excerpt provided to support “generally used” criteria or “not responded adequately” phrasing.
In UC, infliximab (Remicade) is generally used for people with moderate to severe disease who need a biologic to control ongoing inflammation.
No label excerpt provided describing biologic need or “ongoing inflammation” rationale/selection language.
In UC, infliximab (Remicade) is generally used for people with active disease where a faster biologic response is needed.
No label excerpt provided supporting an “active disease” scenario or “faster response” treatment selection.
Remicade is designed to block TNF, a key inflammatory signal in UC.
The provided excerpts do not connect TNF blockade to UC specifically; the label support shown is only general drug descriptor (“TNF blocker”) without UC mechanistic wording.
By reducing TNF activity, Remicade can lower intestinal inflammation.
No label excerpt provided stating this mechanism-outcome framing.
By reducing TNF activity, Remicade can help patients achieve remission.
No Indications/Clinical Studies excerpt provided to support remission claims for UC.
By reducing TNF activity, Remicade can help patients maintain remission.
No Indications/Clinical Studies excerpt provided to support remission maintenance claims for UC.
Infliximab carries class-related risks including serious infections.
Only supported as “increased risk” for serious infections from REMICADE labeling; “class-related” is not explicitly stated in the provided excerpts (minor phrasing mismatch).
The specific monitoring plan for infliximab depends on the patient’s history and other medications.
The provided excerpt states patients should be tested and closely monitored, but does not provide language that the monitoring plan depends on patient history and other medications.
Contradictions
Important Omissions
That REMICADE should not be initiated in patients with an active infection (and that a patient who develops a new infection should be closely monitored with appropriate antimicrobial therapy initiated).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety statements align with boxed warning guidance (serious infections; TB testing; monitoring). However, multiple unsupported efficacy/indication/positioning statements regarding UC could mislead interpretation of when and for whom REMICADE is used, which may indirectly affect safe decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
UC indication/selection and TNF-mechanism/outcome statements are not supported by the prescribing information excerpts provided.
Suggested Improvement
Restrict claims to the provided labeled boxed warning/warnings language for serious infections (including TB testing and close monitoring) and malignancy risks, unless the full Indications and Usage and Clinical Studies label sections are supplied to support UC-specific and remission/response statements.